Kinnate Biopharma Inc.

NasdaqGS:KNTE Stock Report

Market Cap: US$125.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Kinnate Biopharma Future Growth

Future criteria checks 0/6

Kinnate Biopharma is forecast to grow earnings and revenue by 14.6% and 69.1% per annum respectively while EPS is expected to grow by 33.6% per annum.

Key information

14.6%

Earnings growth rate

33.55%

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth rate69.1%
Future return on equityn/a
Analyst coverage

Low

Last updated03 Apr 2024

Recent future growth updates

Recent updates

Analysis Article • Jun 11

Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 04

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 21

FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor

Clinical-stage oncology company Kinnate Biopharma (NASDAQ:KNTE) on Wednesday said it had got a fast track designation from the U.S. FDA for its inhibitor KIN-2787 for the treatment of patients with melanoma, the most serious type of skin cancer. The exact indication for KIN-2787 is for the treatment of patients with BRAF Class II or III alteration-positive and/or NRAS mutation-positive stage IIb to IV malignant melanoma that is metastatic or unresectable. The FDA's Fast Track approval is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. KIN-2787 is being evaluated in an ongoing phase 1 clinical trial in patients with solid tumors harboring BRAF alterations or who have NRAS mutant melanoma, KNTE said in a statement. The fast track nod for KIN-2787 follows an earlier orphan drug designation granted by the FDA for the treatment of stage IIb-IV melanoma. KNTE stock +4.8% to $12.65 after hours.
Analysis Article • Sep 15

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 11

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Kinnate Biopharma press release (NASDAQ:KNTE): Q2 GAAP EPS of -$0.62 beats by $0.03. As of June 30, 2022, the total of cash and cash equivalents and investments was $279.6 million, exclusive of Kinnjiu’s cash.
Analysis Article • May 15

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 24

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Oct 09

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 22

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 03

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Earnings and Revenue Growth Forecasts

NasdaqGS:KNTE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-69-36-232
12/31/2025N/A-53-37-373
12/31/2024N/A-59-54-544
12/31/2023N/A-113-100-100N/A
9/30/2023N/A-127-107-106N/A
6/30/2023N/A-127-102-102N/A
3/31/2023N/A-122-96-96N/A
12/31/2022N/A-116-92-89N/A
9/30/2022N/A-111-91-88N/A
6/30/2022N/A-105-88-85N/A
3/31/2022N/A-99-81-79N/A
12/31/2021N/A-90-72-71N/A
9/30/2021N/A-77-62-62N/A
6/30/2021N/A-63-53-53N/A
3/31/2021N/A-49-41-41N/A
12/31/2020N/A-36-30-30N/A
9/30/2020N/A-26-20-20N/A
12/31/2019N/A-10-11-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KNTE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KNTE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KNTE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KNTE is forecast to have no revenue next year.

High Growth Revenue: KNTE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KNTE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/04/03 06:07
End of Day Share Price 2024/04/03 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kinnate Biopharma Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paul ChoiGoldman Sachs
Roger SongJefferies LLC
Christopher RaymondPiper Sandler Companies